10:35 EDT Sarepta (SRPT) jumps 5% to $42.11 after UK allows Elevidys study to continue
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta announces MHRA says ENVISION dosing may continue as planned
- Buy Rating on Sarepta Therapeutics: Valuation Disconnect and Growth Potential Highlighted by Elevidys Approval
- Sarepta price target lowered to $84 from $169 at JPMorgan
- Positive Outlook for Sarepta Therapeutics Amid Elevidys Expansion and Strategic Collaborations
- Sarepta reports positive ELEVIDYS protein expression data in young patients